aldosterone has been researched along with Atherosclerosis in 47 studies
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors sought to determine the relationship of circulating angiotensinogen levels to ethnicity, sex, BP, incident hypertension, and prevalent hypertension in a modern sex-balanced ethnically diverse cohort." | 8.31 | Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). ( Brambatti, M; Carlisle, SM; DeFilippis, AP; Kahlon, T; Michos, ED; Morgan, ES; Mostacero, DO; Mousavi, H; Mullick, AE; Ouyang, P; Shah, SJ; Tami, Y; Trainor, PJ; Tsimikas, S, 2023) |
| " The sample consisted of 1970 men and women from the Multi-Ethnic Study of Atherosclerosis who were free of clinical cardiovascular disease at baseline and had blood assayed for adiponectin, leptin, plasma renin activity (PRA) and aldosterone." | 7.81 | The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. ( Allison, MA; Cushman, M; Jenny, NS; McClelland, RL; Rifkin, D, 2015) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 7.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "The aldosterone group was composed by 615 participants, mean age 61." | 5.91 | Cardiovascular Interactions of Renin-Angiotensin-Aldosterone System Assessed by Cardiac Magnetic Resonance: The Multi-Ethnic Study of Atherosclerosis. ( Allison, M; Bluemke, DA; Donekal, S; Lima, JAC; Marques, MD; Murthy, VL; Ostovaneh, MR; Ouyang, P; Rochitte, CE; Shah, RV; Tracy, RP; Varadarajan, V; Venkatesh, BA; Wu, CO; Yoneyama, K, 2023) |
| "Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin." | 5.56 | Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020) |
| "Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status." | 5.43 | Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. ( Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R, 2016) |
| "Aldosterone was associated with higher SBP only in Hispanics (2." | 5.40 | Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis. ( Allison, MA; Budoff, M; Ix, JH; Jenny, NS; Khaki, AR; McClelland, RL; Rifkin, DE; Watson, K, 2014) |
| "Aldosterone treatment increased lipid content of plaques (2." | 5.39 | Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. ( Armani, A; Bagley, J; Caprio, M; Carmeliet, P; Chen, WS; Galayda, C; Jaffe, IZ; McGraw, AP; Nickerson, H, 2013) |
| "Aldosterone is a well-recognized cardiovascular risk (CVR) factor and is related to inflammatory processes." | 5.33 | Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. ( Cascella, T; Colao, A; Di Biase, S; Giallauria, F; Labella, D; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Tauchmanovà, L; Vigorito, C, 2006) |
| " Still, hopes that CETP inhibition could reduce atherosclerosis were dented when the clinical development of one such inhibitor, torcetrapib, was halted because of an unexpected finding of increased cardiovascular and noncardiovascular mortality against a background of elevated blood pressure and plasma aldosterone levels." | 4.85 | The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors. ( Stroes, ES; Vergeer, M, 2009) |
| "The authors sought to determine the relationship of circulating angiotensinogen levels to ethnicity, sex, BP, incident hypertension, and prevalent hypertension in a modern sex-balanced ethnically diverse cohort." | 4.31 | Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). ( Brambatti, M; Carlisle, SM; DeFilippis, AP; Kahlon, T; Michos, ED; Morgan, ES; Mostacero, DO; Mousavi, H; Mullick, AE; Ouyang, P; Shah, SJ; Tami, Y; Trainor, PJ; Tsimikas, S, 2023) |
| " The sample consisted of 1970 men and women from the Multi-Ethnic Study of Atherosclerosis who were free of clinical cardiovascular disease at baseline and had blood assayed for adiponectin, leptin, plasma renin activity (PRA) and aldosterone." | 3.81 | The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis. ( Allison, MA; Cushman, M; Jenny, NS; McClelland, RL; Rifkin, D, 2015) |
| "Cilostazol (CILO), a selective inhibitor of phosphodiesterase 3 with potent antithrombotic property, has been shown to have a vasculoprotective effect in atherosclerosis animal models due to its potential anti-inflammatory and antioxidant actions." | 3.76 | Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. ( Hirata, Y; Hirono, Y; Sakurada, M; Sekizawa, N; Suzuki, N; Yoshimoto, T, 2010) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 3.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "Primary aldosteronism has been shown to represent 8-13% (rather than <1%) of unselected hypertensive patients, and patients with primary aldosteronism to have higher indices of cardiovascular damage than controls of the same age, sex, and BP status." | 2.44 | The role of aldosterone and mineralocorticoid receptors in cardiovascular disease. ( Funder, JW, 2007) |
| "Atherosclerosis is characterized by the thickening of the arterial wall and is the primary cause of coronary artery disease and cerebrovascular disease, two of the most common causes of illness and death worldwide." | 2.44 | Translating molecular discoveries into new therapies for atherosclerosis. ( Daugherty, A; Rader, DJ, 2008) |
| "The aldosterone group was composed by 615 participants, mean age 61." | 1.91 | Cardiovascular Interactions of Renin-Angiotensin-Aldosterone System Assessed by Cardiac Magnetic Resonance: The Multi-Ethnic Study of Atherosclerosis. ( Allison, M; Bluemke, DA; Donekal, S; Lima, JAC; Marques, MD; Murthy, VL; Ostovaneh, MR; Ouyang, P; Rochitte, CE; Shah, RV; Tracy, RP; Varadarajan, V; Venkatesh, BA; Wu, CO; Yoneyama, K, 2023) |
| "Evidence of primary aldosteronism physiology was prevalent (11." | 1.72 | Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study. ( Ballantyne, CM; Boerwinkle, E; Brown, JM; Claggett, BL; Coresh, J; Grams, ME; Shah, AM; Solomon, SD; Vaidya, A; Wang, Z; Wijkman, MO; Yu, B, 2022) |
| "Atherosclerosis is a progressive vascular disease representing the primary cause of morbidity and mortality in developed countries." | 1.56 | Altered Tregs Differentiation and Impaired Autophagy Correlate to Atherosclerotic Disease. ( Armani, A; Caprio, M; Cecconi, F; De Zio, D; Filippini, A; Giampietri, C; Mammi, C; Mandatori, S; Marzolla, V; Pacella, I; Padula, F; Piconese, S; Savoia, C; Starace, D; Taurino, M; Vitiello, L, 2020) |
| "Aldosterone was associated with various markers of inflammation and metabolic dysregulation, which partly differed from the associations observed for renin." | 1.56 | Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity. ( Danser, AHJ; de Graaf, J; Deinum, J; Joosten, LAB; Netea, MG; Riksen, NP; Rutten, J; Schraa, K; Ter Horst, R; van den Munckhof, ICL; van der Heijden, CDCC, 2020) |
| "Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status." | 1.43 | Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. ( Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R, 2016) |
| "Aldosterone was associated with higher SBP only in Hispanics (2." | 1.40 | Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis. ( Allison, MA; Budoff, M; Ix, JH; Jenny, NS; Khaki, AR; McClelland, RL; Rifkin, DE; Watson, K, 2014) |
| "Atherosclerosis is a chronic inflammatory disease in the vessel." | 1.40 | Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells. ( Liu, J; Pang, X; Wang, S; Wu, D; Zhang, X; Zhao, J, 2014) |
| "Aldosterone treatment increased lipid content of plaques (2." | 1.39 | Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism. ( Armani, A; Bagley, J; Caprio, M; Carmeliet, P; Chen, WS; Galayda, C; Jaffe, IZ; McGraw, AP; Nickerson, H, 2013) |
| "Aldosterone is a steroid hormone that signals through renal mineralocorticoid receptors (MRs) to regulate blood pressure." | 1.36 | Placental growth factor mediates aldosterone-dependent vascular injury in mice. ( Aronovitz, M; Carmeliet, P; Ehsan, A; Jaffe, IZ; McGraw, AP; Mendelsohn, ME; Mohammad, NN; Newfell, BG; Perreault, RE, 2010) |
| " We investigated the effect of a combination of eplerenone, a selective aldosterone antagonist, and enalapril, an angiotensin-converting enzyme inhibitor, on NO bioavailability and spontaneous atherosclerotic changes." | 1.35 | Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K, 2008) |
| "Aldosterone is a well-recognized cardiovascular risk (CVR) factor and is related to inflammatory processes." | 1.33 | Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. ( Cascella, T; Colao, A; Di Biase, S; Giallauria, F; Labella, D; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Tauchmanovà, L; Vigorito, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (29.79) | 29.6817 |
| 2010's | 25 (53.19) | 24.3611 |
| 2020's | 7 (14.89) | 2.80 |
| Authors | Studies |
|---|---|
| Parksook, WW | 1 |
| Williams, GH | 1 |
| Brown, JM | 1 |
| Wijkman, MO | 1 |
| Claggett, BL | 1 |
| Shah, AM | 1 |
| Ballantyne, CM | 1 |
| Coresh, J | 1 |
| Grams, ME | 1 |
| Wang, Z | 1 |
| Yu, B | 1 |
| Boerwinkle, E | 1 |
| Vaidya, A | 2 |
| Solomon, SD | 1 |
| Trainor, PJ | 1 |
| Brambatti, M | 1 |
| Carlisle, SM | 1 |
| Mullick, AE | 1 |
| Shah, SJ | 1 |
| Kahlon, T | 1 |
| Mostacero, DO | 1 |
| Mousavi, H | 1 |
| Morgan, ES | 1 |
| Tami, Y | 1 |
| Michos, ED | 1 |
| Ouyang, P | 2 |
| Tsimikas, S | 1 |
| DeFilippis, AP | 1 |
| Varadarajan, V | 1 |
| Marques, MD | 1 |
| Venkatesh, BA | 1 |
| Allison, M | 2 |
| Ostovaneh, MR | 1 |
| Yoneyama, K | 1 |
| Donekal, S | 1 |
| Shah, RV | 1 |
| Murthy, VL | 1 |
| Wu, CO | 1 |
| Tracy, RP | 1 |
| Rochitte, CE | 1 |
| Bluemke, DA | 1 |
| Lima, JAC | 1 |
| Mandatori, S | 1 |
| Pacella, I | 1 |
| Marzolla, V | 1 |
| Mammi, C | 1 |
| Starace, D | 1 |
| Padula, F | 1 |
| Vitiello, L | 1 |
| Armani, A | 2 |
| Savoia, C | 1 |
| Taurino, M | 1 |
| De Zio, D | 1 |
| Giampietri, C | 1 |
| Piconese, S | 1 |
| Cecconi, F | 1 |
| Caprio, M | 2 |
| Filippini, A | 1 |
| Unkart, JT | 1 |
| Allison, MA | 3 |
| Abdelmalek, JA | 1 |
| Jenny, NS | 3 |
| McClelland, RL | 3 |
| Budoff, M | 2 |
| Ix, JH | 2 |
| Rifkin, DE | 2 |
| van der Heijden, CDCC | 2 |
| Ter Horst, R | 1 |
| van den Munckhof, ICL | 1 |
| Schraa, K | 1 |
| de Graaf, J | 1 |
| Joosten, LAB | 2 |
| Danser, AHJ | 1 |
| Netea, MG | 2 |
| Deinum, J | 2 |
| Rutten, J | 1 |
| Riksen, NP | 2 |
| Concistrè, A | 1 |
| Petramala, L | 1 |
| Bisogni, V | 1 |
| Mezzadri, M | 1 |
| Olmati, F | 1 |
| Saracino, V | 1 |
| Oliviero, G | 1 |
| Bonvicini, M | 1 |
| Tonnarini, G | 1 |
| Iannucci, G | 1 |
| Letizia, C | 1 |
| McGraw, AP | 4 |
| Bagley, J | 1 |
| Chen, WS | 1 |
| Galayda, C | 1 |
| Nickerson, H | 1 |
| Carmeliet, P | 2 |
| Jaffe, IZ | 5 |
| McCurley, A | 2 |
| McGraw, A | 1 |
| Pruthi, D | 1 |
| Preston, IR | 1 |
| Khaki, AR | 1 |
| Watson, K | 1 |
| Cushman, M | 1 |
| Rifkin, D | 1 |
| Zhang, X | 1 |
| Liu, J | 1 |
| Pang, X | 1 |
| Zhao, J | 1 |
| Wang, S | 1 |
| Wu, D | 1 |
| Brown, J | 1 |
| de Boer, IH | 1 |
| Robinson-Cohen, C | 1 |
| Siscovick, DS | 1 |
| Kestenbaum, B | 1 |
| Matsuda, Y | 1 |
| Kawate, H | 1 |
| Matsuzaki, C | 1 |
| Sakamoto, R | 1 |
| Shibue, K | 1 |
| Ohnaka, K | 1 |
| Anzai, K | 1 |
| Nomura, M | 1 |
| Takayanagi, R | 1 |
| Krog, AH | 1 |
| Thorsby, PM | 1 |
| Sahba, M | 1 |
| Pettersen, EM | 1 |
| Sandven, I | 1 |
| Jørgensen, JJ | 1 |
| Sundhagen, JO | 1 |
| Kazmi, SS | 1 |
| Pellegrin, M | 1 |
| Alonso, F | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Braunersreuther, V | 1 |
| Mach, F | 1 |
| Haefliger, JA | 1 |
| Hayoz, D | 1 |
| Berthelot, A | 1 |
| Nussberger, J | 1 |
| Laurant, P | 1 |
| Mazzolai, L | 1 |
| Vergeer, M | 1 |
| Stroes, ES | 1 |
| Sakurada, M | 1 |
| Yoshimoto, T | 1 |
| Sekizawa, N | 1 |
| Hirono, Y | 1 |
| Suzuki, N | 1 |
| Hirata, Y | 1 |
| Martinez, FA | 1 |
| Gamliel-Lazarovich, A | 2 |
| Gantman, A | 2 |
| Coleman, R | 2 |
| Jeng, AY | 1 |
| Kaplan, M | 1 |
| Keidar, S | 2 |
| Newfell, BG | 2 |
| Aronovitz, M | 1 |
| Mohammad, NN | 2 |
| Perreault, RE | 1 |
| Ehsan, A | 2 |
| Mendelsohn, ME | 2 |
| Putintsev, AM | 1 |
| Shraer, TI | 1 |
| Sergeev, VN | 1 |
| Maslov, MG | 1 |
| Strukova, OA | 1 |
| Mangoni, AA | 1 |
| Knights, KM | 1 |
| Iyer, LK | 1 |
| Rosano, G | 1 |
| Huang, PL | 1 |
| Hannemann, A | 1 |
| Wallaschofski, H | 1 |
| Lüdemann, J | 1 |
| Völzke, H | 1 |
| Markus, MR | 1 |
| Rettig, R | 1 |
| Lendeckel, U | 1 |
| Reincke, M | 1 |
| Felix, SB | 1 |
| Empen, K | 1 |
| Nauck, M | 1 |
| Dörr, M | 1 |
| Hillaert, MA | 2 |
| Lentjes, EG | 2 |
| Beygui, F | 2 |
| Kemperman, H | 2 |
| Asselbergs, FW | 1 |
| Nathoe, HM | 2 |
| Agostoni, P | 1 |
| Voskuil, M | 1 |
| Ivanes, F | 1 |
| Jude, B | 1 |
| Bertrand, ME | 1 |
| Pasterkamp, G | 1 |
| van der Graaf, Y | 2 |
| Doevendans, PA | 2 |
| Montalescot, G | 2 |
| Van Belle, E | 2 |
| Tomaschitz, A | 1 |
| Pilz, S | 1 |
| Ritz, E | 1 |
| Grammer, T | 1 |
| Amrein, K | 1 |
| Merger, S | 1 |
| Meinitzer, A | 1 |
| Winkelmann, BR | 1 |
| Boehm, BO | 1 |
| März, W | 1 |
| Tikellis, C | 1 |
| Pickering, RJ | 1 |
| Tsorotes, D | 1 |
| Huet, O | 1 |
| Chin-Dusting, J | 1 |
| Cooper, ME | 1 |
| Thomas, MC | 1 |
| Lu, H | 1 |
| Wu, C | 1 |
| Howatt, DA | 1 |
| Balakrishnan, A | 1 |
| Charnigo, RJ | 1 |
| Cassis, LA | 1 |
| Daugherty, A | 2 |
| Wassink, AM | 1 |
| Raz-Pasteur, A | 1 |
| GERASIMOVA, EN | 1 |
| Strawn, WB | 1 |
| Bodary, PF | 1 |
| Sambaziotis, C | 1 |
| Wickenheiser, KJ | 1 |
| Rajagopalan, S | 1 |
| Pitt, B | 1 |
| Eitzman, DT | 1 |
| Suzuki, J | 1 |
| Iwai, M | 1 |
| Mogi, M | 1 |
| Oshita, A | 1 |
| Yoshii, T | 1 |
| Higaki, J | 2 |
| Horiuchi, M | 1 |
| Schiffrin, EL | 1 |
| Kurata, M | 1 |
| Okura, T | 1 |
| Watanabe, S | 1 |
| Fukuoka, T | 1 |
| Cascella, T | 1 |
| Palomba, S | 1 |
| Tauchmanovà, L | 1 |
| Manguso, F | 1 |
| Di Biase, S | 1 |
| Labella, D | 1 |
| Giallauria, F | 1 |
| Vigorito, C | 1 |
| Colao, A | 1 |
| Lombardi, G | 1 |
| Orio, F | 1 |
| Funder, JW | 1 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Brown, NJ | 1 |
| Shapiro, Y | 1 |
| Boaz, M | 1 |
| Matas, Z | 1 |
| Fux, A | 1 |
| Shargorodsky, M | 1 |
| Imanishi, T | 1 |
| Ikejima, H | 1 |
| Tsujioka, H | 1 |
| Kuroi, A | 1 |
| Kobayashi, K | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
| Rader, DJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiometabolic Effects of Eplerenone in HIV Infection[NCT02629094] | Phase 2 | 5 participants (Actual) | Interventional | 2015-12-02 | Terminated | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | -0.33 |
Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | 13 |
11 reviews available for aldosterone and Atherosclerosis
| Article | Year |
|---|---|
Aldosterone and cardiovascular diseases.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Humans; H | 2023 |
The mineralocorticoid receptor as a modulator of innate immunity and atherosclerosis.
Topics: Aldosterone; Animals; Arteries; Atherosclerosis; Humans; Immunity, Innate; Inflammation Mediators; M | 2018 |
Smooth muscle cell mineralocorticoid receptors: role in vascular function and contribution to cardiovascular disease.
Topics: Aging; Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Disease | 2013 |
Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Disease Progression; | 2013 |
The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Topics: Aldosterone; Amides; Animals; Anticholesteremic Agents; Atherosclerosis; Blood Pressure; Cholesterol | 2009 |
[Non-steroidal anti-inflammatory drugs and risk of stroke in older patients: current controversies and research directions].
Topics: Age Factors; Aged; Aged, 80 and over; Aldosterone; Anti-Inflammatory Agents, Non-Steroidal; Atherosc | 2011 |
Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data.
Topics: Aldosterone; Atherosclerosis; Humans; Mineralocorticoid Receptor Antagonists; Renin | 2011 |
Effects of aldosterone on the vasculature.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Endothelium, Vascular; Humans; Muscle, Smooth, | 2006 |
The role of aldosterone and mineralocorticoid receptors in cardiovascular disease.
Topics: Aldosterone; Animals; Atherosclerosis; Cardiovascular Diseases; Heart Failure; Humans; Hyperaldoster | 2007 |
Aldosterone and vascular inflammation.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Cardiovascular Diseases; Humans; Inflammation; | 2008 |
Translating molecular discoveries into new therapies for atherosclerosis.
Topics: Aldosterone; Animals; Atherosclerosis; Humans; Inflammation; Lipoproteins; Renin-Angiotensin System; | 2008 |
2 trials available for aldosterone and Atherosclerosis
| Article | Year |
|---|---|
Perioperative humoral stress response to laparoscopic versus open aortobifemoral bypass surgery.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Aorta; Atherosclerosis; Biomarkers; Coronary Artery | 2017 |
Relationship between plasma aldosterone concentration and soluble cellular adhesion molecules in patients referred to coronary angiography.
Topics: Aged; Aldosterone; Atherosclerosis; Cohort Studies; Coronary Angiography; E-Selectin; Europe; Female | 2011 |
34 other studies available for aldosterone and Atherosclerosis
| Article | Year |
|---|---|
Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study.
Topics: Aldosterone; Atherosclerosis; Atrial Fibrillation; Heart Atria; Heart Failure; Humans; Hyperaldoster | 2022 |
Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA).
Topics: Adult; Aldosterone; Angiotensinogen; Atherosclerosis; Blood Pressure; Female; Humans; Hypertension; | 2023 |
Cardiovascular Interactions of Renin-Angiotensin-Aldosterone System Assessed by Cardiac Magnetic Resonance: The Multi-Ethnic Study of Atherosclerosis.
Topics: Aged; Aldosterone; Atherosclerosis; Cardiovascular System; Female; Humans; Magnetic Resonance Spectr | 2023 |
Altered Tregs Differentiation and Impaired Autophagy Correlate to Atherosclerotic Disease.
Topics: Aldosterone; Animals; Apolipoproteins E; Atherosclerosis; Autophagy; Cell Differentiation; Cell Pola | 2020 |
Relation of Plasma Renin Activity to Subclinical Peripheral and Coronary Artery Disease (from the Multiethnic Study of Atherosclerosis).
Topics: Aldosterone; Ankle Brachial Index; Atherosclerosis; Biomarkers; Coronary Artery Disease; Female; Hum | 2020 |
Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.
Topics: Aged; Aged, 80 and over; Aldosterone; Atherosclerosis; Biomarkers; Carotid Arteries; Cross-Sectional | 2020 |
Subclinical atherosclerosis due to increase of plasma aldosterone concentrations in essential hypertensive individuals.
Topics: Adult; Aldosterone; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carotid Intima-Media Thicknes | 2019 |
Aldosterone increases early atherosclerosis and promotes plaque inflammation through a placental growth factor-dependent mechanism.
Topics: Aldosterone; Animals; Aorta, Abdominal; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Chemoki | 2013 |
Association of renin and aldosterone with ethnicity and blood pressure: the Multi-Ethnic Study of Atherosclerosis.
Topics: Aged; Aged, 80 and over; Aldosterone; Asian People; Atherosclerosis; Biomarkers; Black or African Am | 2014 |
The associations of adipokines with selected markers of the renin-angiotensinogen-aldosterone system: the multi-ethnic study of atherosclerosis.
Topics: Adiponectin; Aged; Aldosterone; Antihypertensive Agents; Atherosclerosis; Body Mass Index; Female; H | 2015 |
Aldosterone induces C-reactive protein expression via MR-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells.
Topics: Aldosterone; Animals; Atherosclerosis; C-Reactive Protein; Flavonoids; Gene Expression Regulation; M | 2014 |
Aldosterone, parathyroid hormone, and the use of renin-angiotensin-aldosterone system inhibitors: the multi-ethnic study of atherosclerosis.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Asian; Atheroscleros | 2015 |
Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness | 2016 |
Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes.
Topics: Aldosterone; Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cholesterol; Citrate (si)- | 2009 |
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cilostazol; Disease Mo | 2010 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Apolipoproteins E; Atherosclerosis; Cell Line; Cytochrome P-450 CYP11B2; Diet, | 2010 |
Placental growth factor mediates aldosterone-dependent vascular injury in mice.
Topics: Aldosterone; Animals; Atherosclerosis; Blood Vessels; Clinical Trials as Topic; Humans; Male; Mice; | 2010 |
[Variants of surgical management for severe arterial hypertension combined with type 2 diabetes mellitus].
Topics: Adult; Aged; Aldosterone; Atherosclerosis; Cadaver; Diabetes Mellitus, Type 2; Female; Follow-Up Stu | 2010 |
Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Cells, Cultured; Dactinomycin; Endothelium, Vascular; | 2011 |
Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endothelial dysfunction in young to middle-aged subjects.
Topics: Adult; Age Factors; Aging; Aldosterone; Atherosclerosis; Biomarkers; Brachial Artery; Chi-Square Dis | 2011 |
Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse.
Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Aor | 2012 |
Differential effects of dietary sodium intake on blood pressure and atherosclerosis in hypercholesterolemic mice.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cholesterol; Diet, High-Fat; Dose-Resp | 2013 |
Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease.
Topics: Aged; Aldosterone; Atherosclerosis; Biomarkers; Cohort Studies; Coronary Artery Disease; Female; Fol | 2013 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted | 2014 |
[ISOLATION OF ALDOSTERONE FROM THE URINE OF PATIENTS WITH ATHEROSCLEROSIS].
Topics: Aldosterone; Arteriosclerosis; Atherosclerosis; Blood Pressure Determination; Cholesterol; Rabbits; | 1963 |
Eplerenone antagonizes atherosclerosis, but what is the agonist?
Topics: Aldosterone; Animals; Atherosclerosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; R | 2005 |
Aldosterone promotes thrombosis formation after arterial injury in mice.
Topics: Aldosterone; Animals; Atherosclerosis; Carotid Artery Injuries; Hyperaldosteronism; Male; Mice; Mice | 2006 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Chole | 2006 |
Osteopontin and carotid atherosclerosis in patients with essential hypertension.
Topics: Adult; Aged; Aldosterone; Atherosclerosis; Biomarkers; Carotid Artery Diseases; Carotid Artery, Comm | 2006 |
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome.
Topics: Adult; Aldosterone; Atherosclerosis; Cardiovascular Diseases; Case-Control Studies; Causality; Femal | 2006 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
The association between the renin-angiotensin-aldosterone system and arterial stiffness in young healthy subjects.
Topics: Adult; Aldosterone; Arteries; Atherosclerosis; Blood Flow Velocity; Blood Pressure; Female; Humans; | 2008 |
Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Topics: Acetylcholine; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Athe | 2008 |